Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

NMPA Grants Conditional Approval to Tazemetostat for EZH2-Mutant R/R Follicular Lymphoma

March 21st 2025

China’s NMPA has granted conditional approval to the EZH2 inhibitor tazemetostat for patients with relapsed/refractory EZH2-mutated follicular lymphoma.

PLN-101095/Pembrolizumab Has Early Activity in ICI-Refractory Advanced Solid Tumors

March 21st 2025

PLN-101095 plus pembrolizumab was safe and active in immune checkpoint inhibitor–refractory advanced solid tumors.

Improving Outcomes for Patients With Anal Cancer By Raising Awareness

March 21st 2025

For Anal Cancer Awareness Day, Sheela Rao, MBBS, MD, FRCP, discusses present and upcoming treatment strategies, unmet needs, and the future of the field.

First-Line Atezolizumab Is Suitable in Platinum-Based Chemotherapy Ineligible mUC

March 21st 2025

Real-world data showed that atezolizumab provided a benefit and was safe in patients with platinum-ineligible mUC and high comorbidities/functional status.

IL-Agonist NKTR-255 Shows Ability to Enhance Responses to CAR T-Cell Therapy in R/R LBCL

March 20th 2025

Sairah Ahmed, MD, discusses findings from a phase 2 trial of NKTR-255 after CD19-directed CAR T-cell therapy in relapsed/refractory LBCL.

HLX22 Receives FDA Orphan Drug Designation in Gastric Cancer

March 19th 2025

The FDA has granted orphan drug designation to HLX22 for the treatment of patients with gastric cancer based on positive data from the HLX22-GC-201 study.

Fruquintinib/Sintilimab Generates Favorable PFS Outcomes in Advanced RCC

March 19th 2025

Second-line fruquintinib plus sintilimab improved PFS, ORR, and DOR outcomes vs everolimus or axitinib monotherapy in advanced/metastatic RCC.

CA19-9 Plus Liquid Biopsy Represents Diagnostic Biomarker of Interest for Early-Stage Pancreatic Cancer Detection

March 19th 2025

Ajay Goel, PhD, AGAF, discusses the potential utility of CA19-9 with an exosome-based liquid biopsy as a diagnostic biomarker in early-stage pancreatic cancer.

Nadofaragene Firadenovec Is Effective With Beneficial Dosing Schedule in Real-World for BCG-Unresponsive NMIBC

March 18th 2025

Mark Tyson II, MD, MPH, and Jacob Moyer, BS, detail findings from the first real-world study of nadofaragene firadenovec in BCG-unresponsive NMIBC.

Off-the-Shelf CAR T-Cell Therapy P-BCMA-ALLO1 Is Efficacious in Relapsed/Refractory Multiple Myeloma

March 18th 2025

P-BCMA-ALLO1 displayed high response rates and compelling safety in a heavily pretreated population of patients with relapsed/refractory multiple myeloma.

Pembrolizumab Plus Lenvatinib Elicits Clinically Meaningful Responses in Platinum-Resistant HGSOC

March 17th 2025

The combination of pembrolizumab and lenvatinib showed promising activity including durable responses in patients with platinum-resistant HGSOC.

Cyclin E1 Positivity Predicts Response to Azenosertib in Platinum-Resistant Ovarian Cancer

March 16th 2025

Patients with cyclin E1–positive platinum-resistant ovarian cancer experienced a greater response to azenosertib vs the overall DENALI population.

Retifanlimab Adds FDA-Approved Option to Merkel Cell Carcinoma Treatment Landscape

March 14th 2025

Retifanlimab demonstrated durable activity with a tolerable safety profile in patients with chemotherapy-naive MCC.

Liso-Cel Receives European Approval in Relapsed/Refractory Follicular Lymphoma

March 14th 2025

The European Commission has approved liso-cel in relapsed/refractory follicular lymphoma after at least 2 prior lines of systemic therapy.

D-MNA Displays Potential as Noninvasive Therapy in Basal Cell Carcinoma of the Skin

March 14th 2025

Micro-array needles containing doxorubicin displayed safety and early activity in basal cell carcinoma of the skin.

Acalabrutinib Plus Venetoclax and Obinutuzumab Displays High Level of Activity in First-Line High-Risk CLL

March 13th 2025

Acalabrutinib with venetoclax and obinutuzumab was effective and well tolerated in treatment-naive CLL harboring a TP53 aberration.

Navtemadlin Will Be Evaluated as Add-On Therapy to Ruxolitinib in Myelofibrosis

March 13th 2025

The POIESIS trial is evaluating navtemadlin plus ruxolitinib in JAK inhibitor–naive patients with myelofibrosis with a suboptimal response to ruxolitinib.

Maintenance OSE2101 Plus FOLFIRI Meets Primary OS End Point in Advanced/Metastatic PDAC

March 12th 2025

Maintenance treatment with OSE2101 plus FOLFIRI after FOLFIRINOX induction chemotherapy displayed positive topline results in advanced/metastatic PDAC.

Imetelstat Earns EU Approval for Transfusion-Dependent Anemia in Lower-Risk MDS

March 12th 2025

The European Commission has approved imetelstat for the treatment of patients with transfusion-dependent anemia in lower-risk myelodysplastic syndrome.

INB-100 Following HSCT Displays Long-Lasting Activity in Pretreated AML

March 12th 2025

The γδ T-cell agent INB-100 demonstrated a 100% relapse-free survival rate in patients with AML.